Literature DB >> 11264046

Reassuring safety profile of moxifloxacin.

P B Iannini, R Kubin, C Reiter, G Tillotson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11264046     DOI： 10.1086/319615

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.

Authors:  Marcus B Conde; José R Lapa E Silva
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

Review 2.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

3.  Safety of fluoroquinolones: An update.

Authors:  L Mandell; G Tillotson
Journal:  Can J Infect Dis       Date:  2002-01

4.  Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.

Authors:  James R Gavin; Rolf Kubin; Shurjeel Choudhri; Dagmar Kubitza; Hebert Himmel; Rainer Gross; Jutta M Meyer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials.

Authors:  Vincent T Andriole; Daniel C Haverstock; Shurjeel H Choudhri
Journal:  Drug Saf       Date:  2005       Impact factor: 5.228

6.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Authors:  Ian M Rosenthal; Ming Zhang; Kathy N Williams; Charles A Peloquin; Sandeep Tyagi; Andrew A Vernon; William R Bishai; Richard E Chaisson; Jacques H Grosset; Eric L Nuermberger
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.